Boston, MA, April 30, 2014 --(PR.com
)-- Owen Fields, Vice President of Regulatory Strategy for Pfizer Worldwide Research and Development, to Give a Presentation titled “Regulatory Development Issues and Solutions for Combination and Bifunctional Biologics” at the Antibody and Protein Therapeutics Conference, October 23 & 24, 2014 in Boston, MA by GTCBio.
Owen joined Pfizer with the merger of Pfizer and Wyeth. Owen joined Wyeth in 1995, and was responsible for providing regulatory strategy advice for many of Wyeth’s biological products. Prior to Wyeth, Owen served as a review team leader at the United States Food and Drug Administration, where he helped develop and shape US regulatory policy towards food biotechnology. Owen has a BS in Biochemistry and a minor in mathematics from Wichita State University and received his Ph.D. from the Department of Molecular and Cellular Biology at the University of California, Berkeley in 1991.
For more information, please visit www.gtcbio.com/antibodyprotein
The Antibody & Protein Therapeutics Conference will be the premier conference hosting an exciting group of professionals from the academic, biotech, pharmaceutical, and business communities. A balance of both academic and industry experts will facilitate discussion on novel antibody targets, antibody selection methods and strategies, bispecific antibody & fusion proteins, immunomodulatory biotherapy for cancer, and the next generation of protein engineering.
This conference is part of the Protein Discovery Summit 2014, which consists of the following co-located conferences:
1) 3rd Protein Kinases in Drug Discovery
2) Protein Expression, Characterization & Purification
3) 2nd Antibody & Protein Therapeutics
4) 2nd Protein-Protein Interaction
For more information, please visit www.gtcbio.com/antibodyprotein/agenda